- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03933995
Recruitment Status Recruiting
First Posted May 1, 2019
Last update posted May 1, 2019
This is a 5year (+-30 days) long term follow up study to evaluate the safety of autologous bone marrow derived mesenchymal stem cell in erectile dysfunction subject who participated in and completed the Phase 1 trials (refer to ClinicalTrials.gov.Identifier: NCT02344849).
This is a 5year (+-30 days) long term follow up study to evaluate the safety of autologous bone marrow derived mesenchymal stem cell in erectile dysfunction subject who participated in and completed the Phase 1 trials (refer to ClinicalTrials.gov.Identifier: NCT02344849). This trial is planned to evaluate the safety of autologous bone marrow derived mesenchymal stem cell in patients with erectile dysfunction subject. Subjects who signed this follow-up observation informed consent form will participate in a safety assessment (tumor marker test, Serious Adverse Events, cancer incidence, recurrence of prostate cancer and vital sign).
|: Mesenchymal stem cell
Long-term follow up of Mesenchymal stem cell group
Other: no Intervention
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
1. Subjects who treated with Mesenchymal stem cell and enrolled the phase 1
2. Subjects who can agree to participate in the long term observation study by oneself.
- Not Applicable
Contact: JIYEOUN JEONG, bachelor 82-02-3496-0134 email@example.com
Korea, Republic of
Asan medical center
Pharmicell Co., Ltd.
Principal Investigator: Chungsu Kim, Ph.D Asan Medical Center